BioInvent International AB (publ) (BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors Transcript

Operator

Good morning, and welcome to the BioInvent KOL Event. [Operator Instructions]

As a reminder, this call is being recorded, and a replay will be available on the BioInvent website following the conclusion of the event. I will now turn the call over to Martin Welschof, CEO of BioInvent. Please go ahead, Martin.

Martin Welschof
President & CEO

Thank you very much, Wilson, and welcome, everybody, to our BioInvent ovarian cancer KOL Event. And we’re very happy to have with us today Dmitriy Zamarin, MD and PhD, and I will do later a more detailed introduction. Before I do that, I will briefly highlight what we’re trying to cover today, which you see on the agenda, as you can see now. So I will start with some introductory remarks. Then I will hand over to Dmitriy , and he will talk about the ovarian cancer treatment landscape, the medical need, future treatment of ovarian cancer. So really looking forward to that. Then we will hand over to Björn Frendéus, our CSO, and he will really talk about the differentiated mechanism of action that we have for 1808, which I think will be also very interesting and we just recently uploaded actually a manuscript that describes that in detail. Then that will follow by Andres McAllister, our Chief Medical Officer, and he will talk about the clinical data that we have to date, and that also will present it, obviously, will be presented at ASCO.